TLTFF (Theralase Technologies) Interest Expense : $-0.02 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Theralase Technologies's interest expense for the three months ended in Dec. 2024 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Theralase Technologies's Operating Income for the three months ended in Dec. 2024 was $ -0.65 Mil. Theralase Technologies's Interest Expense for the three months ended in Dec. 2024 was $ -0.00 Mil. Theralase Technologies did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Theralase Technologies Interest Expense Historical Data

The historical data trend for Theralase Technologies's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Interest Expense Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.02

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-	-	-

Theralase Technologies Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Theralase Technologies (OTCPK:TLTFF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Theralase Technologies's Interest Expense for the three months ended in Dec. 2024 was $-0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-0.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.14 Mil.

Theralase Technologies's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Theralase Technologies did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

TTX:Germany TTX:Germany TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.